GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil

Purpose To compare biochemical and tumor response rates between two reference centers for pituitary diseases in Brazil after primary and adjuvant therapy with somatostatin receptor ligands (SRL) in acromegaly. Methods Patients were classified as non-responders (NR), partial responders (PR), and full...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine 2021-10, Vol.74 (1), p.146-154
Hauptverfasser:	Manosso, Karina Zanlorenzi Basso, Sampaio, Carolina Labigalini, Kasuki, Leandro, Antunes, Ximene, Gadelha, Monica R., Boguszewski, Cesar Luiz
Format:	Artikel
Sprache:	eng
Schlagworte:	Acromegaly Acromegaly - drug therapy Adult Brazil Diabetes Endocrinology Endocrinology & Metabolism Female Growth hormones Human Growth Hormone Humanities and Social Sciences Humans Insulin-Like Growth Factor I Internal Medicine Life Sciences & Biomedicine Ligands Male Medicine Medicine & Public Health Middle Aged multidisciplinary Neoplasms Octreotide Original Article Peptides, Cyclic Pituitary Receptors, Somatostatin Response rates Science Science & Technology Somatostatin Somatostatin - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose To compare biochemical and tumor response rates between two reference centers for pituitary diseases in Brazil after primary and adjuvant therapy with somatostatin receptor ligands (SRL) in acromegaly. Methods Patients were classified as non-responders (NR), partial responders (PR), and full responders (FR) to 12-month SRL therapy according to: [criteria A] normal IGF-I and random GH (rGH)
ISSN:	1355-008X 1559-0100
DOI:	10.1007/s12020-021-02766-2